These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 38936233

  • 1. Determinants of Bone Mass Accrual in Transgender and Gender Diverse Youth Undergoing Pubertal Suppression Therapy.
    Roberge S, Roberge T, Corathers S, Nasomyont N.
    J Clin Densitom; 2024; 27(3):101505. PubMed ID: 38936233
    [Abstract] [Full Text] [Related]

  • 2. Pubertal Suppression, Bone Mass, and Body Composition in Youth With Gender Dysphoria.
    Navabi B, Tang K, Khatchadourian K, Lawson ML.
    Pediatrics; 2021 Oct; 148(4):. PubMed ID: 34497118
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones.
    van der Loos MATC, Vlot MC, Klink DT, Hannema SE, den Heijer M, Wiepjes CM.
    JAMA Pediatr; 2023 Dec 01; 177(12):1332-1341. PubMed ID: 37902760
    [Abstract] [Full Text] [Related]

  • 7. Bone Density in Transgender Youth on Gender-Affirming Hormone Therapy.
    Roy MK, Bothwell S, Kelsey MM, Ma NS, Moreau KL, Nadeau KJ, Rothman MS, Nokoff NJ.
    J Endocr Soc; 2024 Mar 12; 8(5):bvae045. PubMed ID: 38562129
    [Abstract] [Full Text] [Related]

  • 8. Bone Development in Transgender Adolescents Treated With GnRH Analogues and Subsequent Gender-Affirming Hormones.
    Schagen SEE, Wouters FM, Cohen-Kettenis PT, Gooren LJ, Hannema SE.
    J Clin Endocrinol Metab; 2020 Dec 01; 105(12):e4252-63. PubMed ID: 32909025
    [Abstract] [Full Text] [Related]

  • 9. Low Bone Mineral Density in Early Pubertal Transgender/Gender Diverse Youth: Findings From the Trans Youth Care Study.
    Lee JY, Finlayson C, Olson-Kennedy J, Garofalo R, Chan YM, Glidden DV, Rosenthal SM.
    J Endocr Soc; 2020 Sep 01; 4(9):bvaa065. PubMed ID: 32832823
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy.
    Sanna E, Lami A, Giacomelli G, Alvisi S, Paccapelo A, Seracchioli R, Meriggiola MC.
    Front Endocrinol (Lausanne); 2024 Sep 01; 15():1416121. PubMed ID: 39391880
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Growth in Transgender/Gender-Diverse Youth in the First Year of Treatment With Gonadotropin-Releasing Hormone Agonists.
    Schulmeister C, Millington K, Kaufman M, Finlayson C, Kennedy JO, Garofalo R, Chan YM, Rosenthal SM.
    J Adolesc Health; 2022 Jan 01; 70(1):108-113. PubMed ID: 34315674
    [Abstract] [Full Text] [Related]

  • 15. Pediatric Reference Ranges for Ultradistal Radius Bone Density: Results from the Bone Mineral Density in Childhood Study.
    Kindler JM, Kalkwarf HJ, Lappe JM, Gilsanz V, Oberfield S, Shepherd JA, Kelly A, Winer KK, Zemel BS.
    J Clin Endocrinol Metab; 2020 Oct 01; 105(10):e3529-39. PubMed ID: 32561914
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Progressive bone impairment with age and pubertal development in neurofibromatosis type I.
    Rodari G, Scuvera G, Ulivieri FM, Profka E, Menni F, Saletti V, Esposito S, Bergamaschi S, Ferrante E, Eller-Vainicher C, Esposito S, Arosio M, Giavoli C.
    Arch Osteoporos; 2018 Aug 27; 13(1):93. PubMed ID: 30151698
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Development of Hip Bone Geometry During Gender-Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty.
    van der Loos MA, Hellinga I, Vlot MC, Klink DT, den Heijer M, Wiepjes CM.
    J Bone Miner Res; 2021 May 27; 36(5):931-941. PubMed ID: 33507568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.